MX2018011219A - Trail diseñado por ingenieria para terapia de cancer. - Google Patents

Trail diseñado por ingenieria para terapia de cancer.

Info

Publication number
MX2018011219A
MX2018011219A MX2018011219A MX2018011219A MX2018011219A MX 2018011219 A MX2018011219 A MX 2018011219A MX 2018011219 A MX2018011219 A MX 2018011219A MX 2018011219 A MX2018011219 A MX 2018011219A MX 2018011219 A MX2018011219 A MX 2018011219A
Authority
MX
Mexico
Prior art keywords
cancer therapy
trail
engineered
molecules
engineered trail
Prior art date
Application number
MX2018011219A
Other languages
English (en)
Spanish (es)
Inventor
Hung-yi Chai MARCANTONIO Diana
L Sazinsky Stephen
M Schoeberl Birgit
M Tam Eric
Original Assignee
Merrimack Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrimack Pharmaceuticals Inc filed Critical Merrimack Pharmaceuticals Inc
Publication of MX2018011219A publication Critical patent/MX2018011219A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
MX2018011219A 2016-03-16 2017-03-16 Trail diseñado por ingenieria para terapia de cancer. MX2018011219A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201662309352P 2016-03-16 2016-03-16
US201662323501P 2016-04-15 2016-04-15
US201762445556P 2017-01-12 2017-01-12
PCT/US2017/022789 WO2017161173A1 (en) 2016-03-16 2017-03-16 Engineered trail for cancer therapy

Publications (1)

Publication Number Publication Date
MX2018011219A true MX2018011219A (es) 2019-01-10

Family

ID=58413224

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011219A MX2018011219A (es) 2016-03-16 2017-03-16 Trail diseñado por ingenieria para terapia de cancer.

Country Status (10)

Country Link
US (1) US20190077870A1 (cg-RX-API-DMAC7.html)
EP (1) EP3430034A1 (cg-RX-API-DMAC7.html)
JP (1) JP2019518713A (cg-RX-API-DMAC7.html)
KR (1) KR20180127407A (cg-RX-API-DMAC7.html)
CN (1) CN108884142A (cg-RX-API-DMAC7.html)
AU (1) AU2017234679A1 (cg-RX-API-DMAC7.html)
CA (1) CA3017622A1 (cg-RX-API-DMAC7.html)
IL (1) IL261267A (cg-RX-API-DMAC7.html)
MX (1) MX2018011219A (cg-RX-API-DMAC7.html)
WO (1) WO2017161173A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108026181B (zh) * 2015-10-22 2021-07-02 成都华创生物技术有限公司 一种TRAIL双靶点突变蛋白MuR6S4TR、其制备方法及其应用
CN109641033A (zh) * 2016-06-13 2019-04-16 梅里麦克制药股份有限公司 用基于trail的治疗剂或死亡受体激动剂选择和治疗患者的方法
CN109125709B (zh) * 2018-08-23 2021-10-22 成都华创生物技术有限公司 Trail突变体在制备治疗痤疮药物中的应用及一种制剂
KR102764218B1 (ko) * 2020-10-13 2025-02-11 신동준 반려견의 항암용 재조합 단백질 및 이를 포함하는 반려견을 위한 항암용 조성물

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
JPH0822239B2 (ja) * 1988-07-07 1996-03-06 株式会社蛋白工学研究所 変異ヒト腫傷壊死因子
CA2118508A1 (en) 1992-04-24 1993-11-11 Elizabeth S. Ward Recombinant production of immunoglobulin-like domains in prokaryotic cells
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
PL220113B1 (pl) 1999-01-15 2015-08-31 Genentech Inc Wariant macierzystego polipeptydu zawierającego region Fc, polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania receptora Fc gamma (FcγR), polipeptyd zawierający wariant regionu Fc o zmienionym powinowactwie wiązania noworodkowego receptora Fc (FcRn), kompozycja, wyizolowany kwas nukleinowy, wektor, komórka gospodarza, sposób otrzymywania wariantu polipeptydu, zastosowanie wariantu polipeptydu i sposób otrzymywania wariantu regionu Fc
CA2377585A1 (en) * 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
US7091321B2 (en) 2000-02-11 2006-08-15 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of antibody-based fusion proteins
US6725230B2 (en) 2000-07-18 2004-04-20 Aegis Analytical Corporation System, method and computer program for assembling process data of multi-database origins using a hierarchical display
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP1534335B9 (en) 2002-08-14 2016-01-13 Macrogenics, Inc. Fcgammariib-specific antibodies and methods of use thereof
EP2298805A3 (en) 2002-09-27 2011-04-13 Xencor, Inc. Optimized Fc variants and methods for their generation
DK1562972T3 (da) 2002-10-15 2010-12-06 Facet Biotech Corp Modifikation af FcRn-bindingsaffiniteter eller serumhalveringstider for antistoffer ved mutagenese
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US8101720B2 (en) 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
GB0328261D0 (en) * 2003-12-05 2004-01-07 Univ Groningen Improved cytokine design
CA2552788C (en) 2004-01-12 2013-09-24 Applied Molecular Evolution, Inc. Fc region variants
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
CN101001873B (zh) 2004-08-04 2013-03-13 曼璀克生物科技有限责任公司 Fc区变体
GB0724532D0 (en) * 2007-12-17 2008-01-30 Nat Univ Ireland Trail variants for treating cancer
DK2604693T3 (en) * 2008-07-21 2016-05-30 Apogenix Gmbh Single-chain TNFSF molecules
JP5677972B2 (ja) 2008-11-18 2015-02-25 メリマック ファーマシューティカルズ インコーポレーティッド ヒト血清アルブミンリンカーおよびそのコンジュゲート
ES2548030T3 (es) * 2009-06-01 2015-10-13 Medimmune, Llc Moléculas con semividas prolongadas y usos de las mismas
EP2564188A4 (en) 2010-04-26 2013-09-25 Merrimack Pharmaceuticals Inc TESTS FOR ANTI-MEDICATION ANTIBODIES IN THE PRESENCE OF ENDOGENOUS PROTEIN COMPOUNDS OF THE MEDICINAL PRODUCT
EP2468764A1 (en) * 2010-12-24 2012-06-27 Rijksuniversiteit te Groningen TNF family ligand variants
US9822179B2 (en) * 2011-04-01 2017-11-21 Universitat Stuttgart Recombinant TNF ligand family member polypeptides with antibody binding domain and uses therefor
US20130150566A1 (en) * 2011-07-06 2013-06-13 Targetpharma Laboratories (Changzhou) Co., Ltd Tumor-targeted tnf-related apoptosis-inducing ligand's variant and the application thereof
NO2776305T3 (cg-RX-API-DMAC7.html) * 2014-04-23 2018-01-27
US10428149B2 (en) * 2015-03-18 2019-10-01 Universitat Stuttgart Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof

Also Published As

Publication number Publication date
EP3430034A1 (en) 2019-01-23
KR20180127407A (ko) 2018-11-28
CN108884142A (zh) 2018-11-23
CA3017622A1 (en) 2017-09-21
IL261267A (en) 2018-10-31
AU2017234679A1 (en) 2018-08-30
US20190077870A1 (en) 2019-03-14
WO2017161173A1 (en) 2017-09-21
JP2019518713A (ja) 2019-07-04

Similar Documents

Publication Publication Date Title
PH12018500380A1 (en) Anti-dll3 antibody drug conjugates and methods of use
MX393818B (es) Terapias de combinación para el tratamiento de cáncer.
MX2019003938A (es) Compuestos espirociclicos.
EA201590997A1 (ru) Соединения и способы их применения
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
PH12019501018A1 (en) Pharmaceutical composition, methods for treating and uses thereof
EA201890754A1 (ru) Соединения и способы их применения
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX2017012380A (es) Derivados de maitansinoide, conjugados de los mismos, y metodos de uso.
MY187540A (en) Compounds active towards bromodomains
MX2018007304A (es) Composiciones de interleucina-15 y sus usos.
PH12017500406A1 (en) Novel anti-mfi2 antibodies and methods of use
CL2016002257A1 (es) Anticuerpos anti-mcam y métodos de uso asociados
PH12019502692A1 (en) Anti-cancer combination therapy
MX2015014046A (es) Combinaciones de farmacos para tratar cancer.
MX2018006249A (es) Nuevos anticuerpos anti-emr2 y metodos de uso.
MX2018000715A (es) Metodos para tratar cancer usando apilimod.
MX379271B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
MX379622B (es) Compuestos espirociclicos
MX2017014436A (es) Compuestos biciclicos.
PH12018501455A1 (en) Therapeutic compostions and methods for treating hepatitis b
MX2018010847A (es) Terapia combinada mediante el uso de un conjugado de anticuerpo-farmaco de liv1 (liv1-adc) y agente quimioterapeutico.
MX2018007818A (es) Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso.
MX2018007817A (es) Nuevos anticuerpos anti-mmp16 y metodos para su uso.
EA201990370A1 (ru) Терапия рака, связанная с crebbp